US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
pharma · SBRT · Covid19 · GRTX
Kailera Therapeutics
Galera Therapeutics
Kailera Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Waltham, Massachusetts, United States HQ
2024 Founded
153 Employees
Public company Type
GRTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, Massachusetts, United States
- Founded
- 2024
- Employees
- 153
- Programs
- 17
- Drugs
- 7
- Patents
- 23
Kailera Therapeutics pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kailera Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Kailera Therapeutics in public FDA and regional records.
-
dextromethorphan hydrobromide
Nervous system (N07)US regulatory status: approved. Molecular target: Glutamate receptor ionotropic, NMDA 2A.
- Target
- Glutamate receptor ionotropic, NMDA 2A
- Mechanism
- Glutamate [NMDA] receptor subunit epsilon 1 antagonist
-
Development asset linked to Kailera Therapeutics in public FDA and regional records.
-
Development asset linked to Kailera Therapeutics in public FDA and regional records.
-
Development asset linked to Kailera Therapeutics in public FDA and regional records.